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The crystal structure of vascular endothelial growth factor
(VEGF) refined to 1.93 Å resolution: multiple copy flexibility and
receptor binding
Yves A Muller1†, Hans W Christinger1, Bruce A Keyt2 and Abraham M de Vos1*
Background: Vascular endothelial growth factor (VEGF) is an endothelial cell-
specific angiogenic and vasculogenic mitogen. VEGF also plays a role in
pathogenic vascularization which is associated with a number of clinical
disorders, including cancer and rheumatoid arthritis. The development of
VEGF antagonists, which prevent the interaction of VEGF with its receptor,
may be important for the treatment of such disorders. VEGF is a homodimeric
member of the cystine knot growth factor superfamily, showing greatest
similarity to platelet-derived growth factor (PDGF). VEGF binds to two different
tyrosine kinase receptors, kinase domain receptor (KDR) and Fms-like tyrosine
kinase 1 (Flt-1), and a number of VEGF homologs are known with distinct
patterns of specificity for these same receptors. The structure of VEGF will
help define the location of the receptor-binding site, and shed light on the
differences in specificity and cross-reactivity among the VEGF homologs.
Results: We have determined the crystal structure of the receptor-binding
domain of VEGF at 1.93 Å resolution in a triclinic space group containing
eight monomers in the asymmetric unit. Superposition of the eight copies of
VEGF shows that the β-sheet core regions of the monomers are very similar,
with slightly greater differences in most loop regions. For one loop, the
different copies represent different snapshots of a concerted motion.
Mutagenesis mapping shows that this loop is part of the receptor-binding site
of VEGF.
Conclusions: A comparison of the eight independent copies of VEGF in the
asymmetric unit indicates the conformational space sampled by the protein in
solution; the root mean square differences observed are similar to those seen in
ensembles of the highest precision NMR structures. Mapping the receptor-
binding determinants on a multiple sequence alignment of VEGF homologs,
suggests the differences in specificity towards KDR and Flt-1 may derive from
both sequence variation and changes in the flexibility of binding loops. The
structure can also be used to predict possible receptor-binding determinants
for related cystine knot growth factors, such as PDGF.
Introduction
Angiogenesis is the sprouting of blood capillaries from
pre-existing blood vessels, while vasculogenesis is the de
novo development of blood vessels through differentiation
of early endothelial cells during embryonic development
[1]. Vascular endothelial growth factor (VEGF) has been
identified as an endothelial cell-specific mitogen mediat-
ing both of these processes [1–4]. Heterozygous knock-out
mice lacking a single VEGF allele are not viable beyond
days 11 and 12 in the uterus and show severe abnormal
blood vessel formation [5,6].
Angiogenesis plays a critical role in the pathogenesis of a
variety of disorders such as cancer, proliferative retinopa-
thy and rheumatoid arthritis [1]. Tumor vascularization is
required to overcome tumor ischemia and necrosis; fur-
thermore, aggressive behavior of different carcinomas cor-
relates strongly with the degree of tumor vascularization
[2]. VEGF is released by a variety of tumors; tumor growth
can be suppressed by the administration of anti-VEGF
antibodies in vivo [7]. In addition, diabetic retinopathy, a
leading cause of blindness caused by excessive intraocular
neovascularization, has been linked to elevated VEGF
levels in the eye [8,9]. At the atomic level, these physio-
logical events are initiated by the specific interaction of
VEGF with two receptors, kinase domain receptor (KDR)
and Fms-like tyrosine kinase 1 (Flt-1). Therefore, VEGF
antagonists preventing this interaction might play an
important role in the effective treatment of tumors as well
as pathogenic vascularization in general.
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VEGF is a glycosylated, disulfide-linked homodimer and
is expressed in different isoforms ranging in size from 121
to 206 residues in humans (VEGF121, VEGF165, VEGF189
and VEGF206). The isoforms result from different splicing
events, and all variants share the same 115 N-terminal as
well as six C-terminal residues [10,11]. VEGF165 is the
dominant isoform, while VEGF206 has so far only been
identified in a human fetal liver cDNA library [10].
VEGF165 and VEGF189 bind heparin with high affinity,
and are sequestered to the cell surface or within the extra-
cellular matrix bound to proteoglycans, while VEGF121
does not bind heparin and is thus freely diffusible.
Plasmin cleavage of VEGF165 generates a 110-residue long
N-terminal fragment (the receptor-binding domain) that
no longer binds heparin but is equipotent to VEGF121 in
its ability to induce endothelial cell proliferation [12].
Therefore, the bioavailability of VEGF, in addition to the
control of gene expression, might be triggered by prote-
olytic cleavage of the longer isoforms of VEGF [2] bound
to heparan sulfate proteoglycan [12].
The receptor-binding domain of VEGF shares significant
sequence homology with platelet-derived growth factor
(PDGF) [13,14]. Recently, a number of growth factors were
discovered that share higher sequence homology with
VEGF than PDGF, some of which bind to identical recep-
tors, namely placenta growth factor (PLGF) [15], VEGF-B
[16] and VEGF-C (also named VEGF-related protein
[VRP]) [17,18]. Not much is yet known about the specific
biological roles of these homologs, but VEGF-C appears to
be a growth factor specific for the lymphatic vascular system
[19]. Of the two known receptor tyrosine kinases that bind
VEGF, KDR/Flk-1 (human/murine homolog) and Flt-1,
Flt-1 has the higher affinity for VEGF (KD=10–20 pM [20]
compared to 75–125 pM for the KDR/Flk-1 receptor [21]);
binding of VEGF to the KDR/Flk-1 receptor alone has
been proposed to induce endothelial cell proliferation [22].
PLGF binds to the Flt-1 receptor with high affinity but
not to KDR/Flk-1 [23]. VEGF-C binds to a third receptor
tyrosine kinase called Flt-4 [24], which is not activated
by VEGF [17]; whether or not VEGF-C binds to Flt-1
and KDR/Flk-1 remains controversial [17,18]. Although the
VEGF binding epitopes for the KDR/Flk-1 and Flt-1
receptor have recently been determined [22,25], little is
known at the molecular level about how specificity is
achieved within this group of growth factors.
We have recently determined the crystal structure of a
truncated construct of residues 8–109 of VEGF at 2.5 Å
resolution [25,26]; the structure shows that VEGF is a
member of the cystine knot growth factor superfamily. All
members of this superfamily are dimeric growth factors,
characterized by a cystine knot motif at one end of a con-
served central four-stranded β sheet within each monomer
(see [27–29]). The superfamily can be subdivided into
four distinct families on the basis of sequence homology.
Of the PDGF family, structures are known for PDGF-BB
[30] and VEGF. In the transforming growth factor (TGF)-β
family, structures have been determined for TGF-β1, -β2
and -β3 [31–34], osteogenic protein 1 [35], and glial cell-
line derived neurotrophic factor (GDNF) [36], while
nerve growth factor (NGF) is characteristic of the neuro-
trophins [37,38]. In contrast to the homodimeric dimeriza-
tion observed for the native members of these first three
families, the structure of human chorionic gonadotropin, a
member of the fourth family, reveals a heterodimeric mol-
ecule [39,40]. Each of the homodimeric families shows a
distinct dimerization mode. In VEGF and PDGF the two
monomers are placed in a ‘side-by-side’ orientation linked
by two disulfide bridges, and the twofold axis is perpen-
dicular to the planes of the β sheets. In both the TGF-β
and NGF families the β sheets of the two monomers are
oriented in a ‘face-to-face’ orientation, but in NGF the
twofold axis relating the two monomers is parallel to the
strands, whereas in the TGF-β family it is perpendicular;
there are no intersubunit disulfide bridges in NGF, while
the TGF-β monomers are disulfide-linked.
Here we present the 1.9 Å crystal structure of human
VEGF in a triclinic crystal form containing eight indepen-
dent monomers in the asymmetric unit. The crystal struc-
ture shows that the eight monomers resemble a typical
solution ensemble of protein structures, as determined by
nuclear magnetic resonance (NMR) spectroscopy: a rigid
core is surrounded by more variable loops. In the crystal
structure these loops are associated with higher than
average temperature factors. In contrast to the general
‘random’ variation in these loop conformations, for one of
the loops the eight observed conformations describe a
concerted movement, which we believe represents the
motion of this segment in solution. Mapping mutational
data onto the structure of VEGF reveals that this loop is
implicated in binding to KDR/Flk-1 as well as to the Flt-1
receptor. These data suggest that this loop may be an
important determinant of specificity within the group of
VEGF-like growth factors, and that its flexibility in VEGF
might be necessary for achieving promiscuity in binding to
both KDR and Flt-1.
Results
Accuracy of the model
The structure of the receptor-binding domain of human
VEGF was solved by molecular replacement (MR) and
refined to a crystallographic R value of 20.9% (R free =
27.2%) for all reflections in the resolution shell between
16 and 1.93 Å (Figure 1; Table 1). The P1 unit cell con-
tains eight VEGF molecules, which form four biological
homodimers. All eight molecules (named A to H) are
defined by continuous electron density. The crystallized
fragment of VEGF consisted of residues 8–109, but only
residues 14–106 are well defined in all eight monomers. In
six molecules, one additional N-terminal and one additional
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C-terminal residue are visible, and monomer A also
includes residues 108 and 109. Glu13 and Asp109, when
present, lack density for the sidechain and are modeled as
alanine. The coordinate error of the final model, as deduced
from a Sigmaa plot [41], is about 0.19 Å. Of all the residues,
90.3% have mainchain torsion angles in the most favorable
regions of the Ramachandran plot (Figure 2), as defined
from a statistical compilation of high-resolution structures
[42], and no residues are located in disallowed regions. The
root mean square (rms) deviation from ideal geometry of
the final model is 0.011 Å for bond lengths and 0.030 Å for
bond angle distances.
The average temperature factor of the final model is
47.1 Å2 (Table 1). This is almost identical to the average
temperature factor of 46.8 Å2 observed in the 2.5 Å struc-
ture of VEGF in space group P21 [25]. The average tem-
perature factors of the individual monomers vary from
41.3 Å2 to 52.8 Å2, and in general molecules belonging to
the same dimer exhibit similar overall temperature factors.
The exception is the dimer formed by molecules G and
H, where the average temperature factors are 52.8 Å2 and
43.8 Å2, respectively. This difference may be caused by
the difference in the extent to which these monomers par-
ticipate in crystal-packing contacts, the mobility of mol-
ecule H in the crystal lattice being restricted by an
additional 400 Å2 of buried accessible surface area when
compared to molecule G (see below). Val20 and Ser24
showed hints of alternative conformations in the final
(2Fo–Fc) exp(iαc) electron-density map, but no alternative
conformations were included in the model.
Monomer structure
The overall structure of the VEGF monomer is similar to
that of other cystine knot proteins [27–29,43]. It consists of
a central antiparallel four-stranded β sheet with the charac-
teristic cystine knot at one end (Figure 1). The cystine knot
consists of two disulfide bonds forming a covalently linked
ring structure between two adjacent β strands (β3 and β7),
together with a third disulfide bond penetrating this ring
and connecting the beginning of strands β1 and β4
(Figures 3 and 4a). In NGF a loose ring is formed by a total
of 14 residues, while in all other members of the superfam-
ily a tighter ring is formed by eight residues. This tight ring
Figure 1
Ribbon representation of the structure of the receptor-binding domain
of VEGF. The secondary structure elements of one monomer are
labeled: α1 (residues 16–24), β1 (27–34), α2 (35–39), β2 (46–48),
β3 (51–58), β4 (67–69), β5 (73–83), β6 (89–99) and β7 (103–105).
One monomer of the dimer is shown in blue and the other in red;
disulfide bonds are shown in white and sulfur atoms are in yellow. The
termini of both monomers are labeled; the asterisks denote the termini
of the red monomer. (The figure was prepared with the programs
MOLSCRIPT [65] and RASTER3D [66].)
Table 1
Refinement and model statistics.
Model
Total number of residues 762
Number of molecules (chains A to H) 8
Number of solvent molecules 640
Total nonhydrogen atoms 6782
Average B factor (Å2) 47.1
Average B factor 
molecules A, B, C, D (Å2) 41.3, 43.8, 50.0, 52.1
molecules E, F, G, H (Å2) 43.1, 47.0, 52.8, 43.8
Average B factor of solvent molecules (Å2) 52.1
Diffraction agreement
Resolution (Å) 16.0–1.93
Completeness (%) 94.2
R value (all data) 0.209
Number of reflections 61 827
Free R value 0.272
Number of reflections 7074
Anisotropic correction (Å2) 14.0
Stereochemistry
Rms difference in bond distance (Å)* 0.011
Rms difference in angle distance (Å)* 0.030
Rms ∆B of bonded atoms* 
mainchain (Å2) 2.0
sidechain (Å2) 2.5
*Rms = root mean square.
is characterized by the strict conservation of a glycine
residue (position 59 in VEGF; Figure 3) due to a potential
clash between any sidechain at this position and the knot.
In addition, Gly59 is required to have a positive dihedral φ
angle (the average φ,ψ values of Gly59 in VEGF are
97.8 ± 6.3° and –169.5 ± 3.9°, respectively).
A detailed analysis of the mainchain hydrogen bonds in
VEGF reveals a total of seven β-strand segments (β1 to
β7) and two α-helical segments (α1 and α2) (Figures 1 and
3). The central four-stranded β sheet can be divided into
two separate pairs of β strands (β1 and β3; β5 and β6); only
a single mainchain hydrogen bond is formed between
Met55 and His99 of the two inner strands (Figure 3). In
addition to the lack of regular hydrogen bonding at the
center of the sheet, the β sheet is solvent-exposed from
both sides (Figure 1). Therefore, the cystine knot is prob-
ably important for the stabilization of the fold (Figure 4a).
Interestingly, a second hydrophobic core is formed across
the monomer–monomer subunit interface at the opposite
end of the monomer to the knot (Figure 4b). Residues
involved in this hydrophobic core are from loop β1 to β3
and segment β5 to β6 of one monomer, and the N-terminal
α helix of the other monomer. The lack of an extended
hydrophobic core at the center of the molecule in both the
monomer and the dimer might be the reason for the high
chain mobility as expressed by the high overall tempera-
ture factor of the model.
In the case of NGF it has been suggested that cystine
knot proteins exhibit a more pronounced twist within the
β strands than other proteins [37]. However, although β1
and β3 both contain proline residues, whose dihedral φ
angle values are restrained to significantly higher values
than in regular β strands, the average φ,ψ values of the
strand residues (φ = –109.4 ± 35.1°, ψ = 136.0 ± 32.4°) are
comparable to those observed in α–β proteins [44]. A
similar result is observed for the average dihedral angles
of residues from strands β5 and β6 (φ = –116.5.4 ± 23.3°,
ψ = 139.0 ± 28.1°). Within these assumed strand limits,
therefore, the β strands in VEGF do not deviate from the
regular right-handed twist.
Each VEGF monomer contains three solvent-accessible
loop regions, namely the loops connecting strand β1 to β3,
β3 to β4, and β5 to β6. The segment connecting strands β1
and β3 (residues 35–50) contains a single turn of α helix
(α2), followed by residues in an irregular conformation
and a short segment of β-strand structure (β2). This short
β strand together with neighboring strands β5 and β6 forms
a short, three-stranded antiparallel β sheet at the opposite
end of the monomer to the cystine knot (Figure 3), and
has been shown to be part of the receptor-binding face of
VEGF [25].
Loop β3 to β4 is adjacent to the cystine knot and differs
greatly in length between different cystine knot proteins,
but is similar in length in VEGF and PDGF. Residues in
the loop regions together with the N- and C-terminal
residues display the highest temperature factors in the
VEGF structure.
Dimer structure
The different cystine knot proteins have similar monomer
topologies but differ greatly in the way the dimers are
formed [27]. VEGF and PDGF dimerize in an antiparallel,
side-by-side fashion [25,30] (Figures 1 and 3). In VEGF
the monomers are covalently linked by two symmetrical
disulfide bonds between Cys51 and Cys60. No mainchain
to mainchain hydrogen bonds are formed between the two
neighboring strands β1 and β1′ of the two subunits; the
only intersubunit mainchain hydrogen bonds are found
between Val15 of the N terminus and Thr77′ and Gln79′
of the outer β strand β5 (Figure 3). At the location of the
dimer axis, four water molecules are conserved in all four
independent dimers within the crystals.
The total area buried at the interface between the two
subunits is 2695 ± 28 Å2. Most of this (1730 Å2, or 65% of
the total) is accounted for by the intermolecular hydro-
phobic core located at the opposite end of the molecule to
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Figure 2
Ramachandran representation of the mainchain dihedral angles of all
residues in the asymmetric unit. Glycine residues are indicated by
triangles, all other residues by dots. According to a statistical
compilation of high-resolution structures [42], 90.3% of all non-glycine
residues are located within the most favored regions, 0.8% in
generously allowed regions, and none in the disallowed regions of the
Ramachandran space.
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the cystine knot, consistent with the observation that
there are only a few contacts between the β1 strands of the
two subunits at the center of the dimer. Interestingly, this
hydrophobic core region, containing the most extensive
contacts within the dimer (Figure 4b), is also part of the
receptor-binding site which extends across the subunit
interface [25] (see below).
Solvent structure and crystal packing
The current model includes a total of 640 water molecules
for 762 ordered protein residues. Assigning each water
molecule to individual monomers in the asymmetric unit
yields 117, 90, 58, 65, 97, 74, 54 and 91 water molecules
for monomers A–H, respectively (six water molecules are
counted twice because their assignment was ambiguous).
Each water position was further inspected for conserva-
tion within the different monomers. By applying a 1 Å
distance cut-off after superposition of the monomers, a
total of 72 water molecules were found to be present in all
eight monomers, occupying nine conserved positions. In
addition, 49, 42, 60, 56, 66 and 88 water molecules were
conserved in seven, six, five, four, three and two monomers,
respectively; 207 waters were only observed once.
As a consequence of the lack of space group symmetry,
each monomer has a different crystallographic environment,
which results in significantly different crystal-packing con-
tacts. The area of each monomer buried in crystal-packing
contacts (omitting the monomer–monomer contact of the
biological dimer) is 1270, 1530, 1140, 1100, 1330, 1210, 1220
and 1650 Å2 for monomers A to H, respectively. Thus,
about 20 to 30% of the total 5710 Å2 monomer accessible
surface in the dimer is buried in crystal-packing contacts, a
range typical for protein crystals [45,46]. One contact occurs
several times. This contact involves a local twofold axis and
packs loops β5 to β6 and α2 to β3 of one monomer against
loop β3 to β4 of a second monomer, and vice versa. This
contact is quite extensive (~430 Å2) and includes a pi-stack-
ing interaction between the aromatic sidechains of Phe36
and His86 (data not shown).
Research Article  Loop motion and receptor binding of VEGF Muller et al. 1329
Figure 3
VEGF secondary structure, showing the
mainchain hydrogen-bond pattern observed
within the monomer. Disulfide bridges are
shown in green and the twofold axis of the
dimer is indicated by a black ellipse. β Strands
are shown in red, helical segments in yellow.
All mainchain hydrogen bonds are indicated
by blue arrows (direction: hydrogen-bond
donor (N-H) to hydrogen-bond acceptor (O)).
A distance cut-off of 3.5 Å was used; when
several hydrogen bonds are possible only the
shortest is shown. The mainchain hydrogen
bonds are very strictly conserved within the
eight monomers in the asymmetric unit, and
ambiguity is only observed at the capping of
the helices. For example, in two monomers the
mainchain hydrogen-bond distance between
Tyr25 and Gln22 (residues i and i+3) is
shorter than that between Tyr25 and Tyr21
(residues i and i+4). With the exception of the
absence of the mainchain hydrogen bond
between Lys84 and Gly88 in one monomer,
all mainchain hydrogen bonds between β
strands are strictly conserved in all eight
monomers. Only two mainchain hydrogen
bonds are formed between monomers within
the dimer. These are the bonds between the
N-terminal residue Val15 of one monomer and
Thr77 and Gln79 of the second monomer,
and are indicated by broken lines. The single
glycosylation site in VEGF is at Asn75 [67]
near the beginning of strand β5.
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Discussion
Comparison with PDGF and other cystine knot proteins
The three-dimensional structures of a number of cystine
knot growth factors have been solved in recent years 
and the structures have been reviewed [27–29,43]. The
members of this superfamily exhibit similar monomer
structures but differ in their dimerization mode. As pre-
dicted on the basis of sequence alignments, the dimeriza-
tion mode of VEGF is very similar to that of PDGF-BB.
The monomers of VEGF can be superimposed onto
PDGF-BB with an rms deviation of 1.7 Å (using 73 Cα
atoms, a distance cut-off of 3.8 Å, and the program O [47]);
superimposing the dimers yields an rms deviation of 1.9 Å
(for 124 Cα atoms), indicating that the relative orientation
of the monomers within the dimer is indeed very similar
in both growth factors (Figure 5a).
There are three major differences between VEGF and
PDGF-BB, and it is noteworthy that these differences 
all involve regions important for receptor binding. The
N-terminal segment, which lies across the four-stranded β
sheet of the second monomer, is α helical in VEGF but
forms an extended conformation in PDGF-BB. In VEGF,
this N-terminal α helix forms part of the receptor-binding
face, and mutagenesis has shown that Phe17 from this
helix is an important KDR-binding determinant [25]. To
our knowledge no residues in the extended N terminus of
PDGF have thus far been tested for receptor binding, but
it is tempting to propose that the difference in conforma-
tion of this segment near the N terminus is important for
receptor specificity. The segment connecting strands β1
and β3 in VEGF (residues 35–50) is not resolved in the
structure of PDGF-BB, but sequence alignment shows
this loop is two residues longer in PDGF (see below).
Residues from this segment have been implicated in
receptor binding in both VEGF [25] and PDGF [30]; in
VEGF the segment contains a single helical turn (α2 in
Figure 1) followed by residues in an irregular confor-
mation. It is noteworthy that the conformation of this
segment is similar to that observed in members of the
1330 Structure 1997, Vol 5 No 10
Figure 4
Structural details of VEGF. (a) Stereo
representation of all atoms within the cystine
knot. Water molecules are shown as crosses
if present at equivalent positions in all eight
monomers. (b) Stereo representation showing
the hydrophobic core formed at the opposite
end to the cystine knot and extending across
the monomer–monomer interface. Residues
whose sidechains contribute to this
hydrophobic core are Ile35, Phe47, Val52,
Met78, Ile80, Met94, Phe96 of one monomer
(thin lines) and Val20 of helix α1 from the
second monomer (bold lines). Ends of
segments of the mainchain are indicated by
small spheres.
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TGF-β family (see below). The third major difference
between VEGF and PDGF is a three-residue deletion in
VEGF at turn β5–β6; this is also likely to have implications
for receptor specificity because residues adjacent to this
turn are involved in receptor binding (see below).
Most of the previous comparisons between more distantly-
related members of the cystine knot superfamily were
based on the superposition of the knot itself. The surprising
similarity between VEGF and TGF-β in the segment con-
necting β1 to β3 prompted us to superimpose the opposite
ends of the monomers (Figure 5b). This superposition
yields an rms difference of 2.1 Å for 44 atoms, compared to
1.4 Å for 38 atoms when superimposing the cystine knot
(distance cut-off = 3.8 Å). The superposition shows that in
addition to helix α2, strand β2 is also conserved in both
growth factors, resulting in a very similar, short three-
stranded β sheet at the end of the molecule opposite to the
knot. This three-stranded β sheet is involved in receptor
binding in VEGF [25], and this same region (although on
the opposite face of the sheet) has been proposed to bind to
one of the TGF-β receptors [48]. Recently, a ligand which
might mimic the binding of proteoglycans has been found
to bind to this face in TGF-β3 [34].
Eight copies of VEGF
The crystal structure of VEGF (residues 8–109) contains
eight copies of the monomer in the asymmetric unit.
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Figure 5
Comparison of VEGF with other cystine knot
growth factors. (a) Stereo representation of
the superposition of the structures of VEGF
and PDGF-BB. VEGF is shown in bold lines
and PDGF-BB (PDB entry code 1PDG) in
thin lines. The structures can be
superimposed with an rms deviation of 1.9 Å
for 124 Cα atoms (distance cut-off 3.8 Å,
program O [47]). (b) Superposition of the
structures of VEGF (bold lines) and TGF-β2
(thin lines; PDB entry code 2TGI). Both
growth factors were superimposed using
residues from the opposite end of the
molecule to the cystine knot (rms deviation:
2.1 Å for 44 Cα positions). The superposition
suggests that a structurally conserved
receptor-binding frame is responsible for
receptor recognition in both VEGF and TGF-β
(see text). The ends of mainchain segments
are indicated with small spheres.
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This unusually high number of independent molecules
allows a discussion of protein flexibility observed in crystals
through methods analogous to those used for solution struc-
tures determined by NMR techniques. The average rms
difference for the mainchain atoms (N, Cα, C and O) with
respect to the mean coordinates and calculated for sec-
ondary structure elements only is 0.24 ± 0.06 Å (Figure 6a);
when all atoms of these same residues are used, this
number increases to 0.37 ± 0.11 Å. As expected, the eight
molecules are very similar in the core region of the mol-
ecule. The greatest deviations are found in loop segments
β1 to β2, β3 to β4 and β5 to β6, as well as in the N-terminal
α helix (Figure 6a). All these regions are well defined by
their density. In all eight molecules, residues from or near
the loop regions are involved in crystal-packing contacts;
it is noteworthy that NMR experiments have shown flex-
ibility in the middle of helix α1 [49]. The rms deviations
among the eight copies are similar to the deviations derived
by NMR from the highest-precision ensembles, showing
that a precision comparable to high-resolution X-ray struc-
tures can be achieved by NMR.
The increased conformational diversity in loop regions cor-
relates well with the increase in temperature factors within
the same segments when compared to the low deviations in
the core regions of the molecule (strands β1, β3, β5 and β6)
(Figure 6b). Outside the loop regions, the temperature
factors also show a significant increase at residues 71–74.
These residues connect strand β4 to β5, and the increase
might reflect higher flexibility made possible by the lack of
regular β strand hydrogen bonding between these residues
and the neighboring strand (Figure 3). Despite the higher
temperature factors, the increase in the rms differences at
these residues is less pronounced.
1332 Structure 1997, Vol 5 No 10
Figure 6
Comparison of the eight copies of VEGF. (a)
Average distance deviation per residue from
the geometrically averaged structure
calculated following best-fit superposition of
the mainchain atoms of residues 16–24,
27–39, 46–48, 51–58, 67–69, 73–83,
89–99 and 103–105. Vertical error bars
indicate the rms difference from the average
within the eight monomers. Secondary
structure elements are indicated by horizontal
lines. (b) Average mainchain temperature
factors per residue for all eight monomers.
(c) Angular order parameter plot. The angular
order parameter is defined as the normalized
vector sum of the mainchain dihedral angles
observed in the different copies of VEGF (φ
order parameter, continuous line; ψ order
parameter, dotted line). The decrease in the
angular order parameter at the peptide-bond
between residues 61 and 62 results from a
peptide-bond flip (six monomers in one
conformation, and two in the other). 
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The angular order parameter plot for φ and ψ [50] empha-
sizes the conservation of the dihedral conformation within
the eight copies of VEGF (Figure 6c). The average φ and
ψ order parameters are 0.987 ± 0.048 and 0.981 ± 0.073,
respectively. The most severe decrease in the order para-
meter is observed for the peptide bond between residues
61 and 62 in loop β3 to β4, and results from a partial
peptide flip. The order parameter is also much lower for
residues 87 and 88 in loop β5 to β6. Interestingly, the
largest reduction within this loop is not observed at the tip
of the loop but for residues adjacent to the loop, namely at
the beginning of strand β6. A small but significant reduc-
tion is also observed for residues at the end of strand β5.
It has been shown that although crystal-packing contacts
induce conformational diversity, the conformations ‘frozen’
within the crystals represent true low-energy conforma-
tions [46]. We decided to study in more detail the confor-
mational diversity observed in the N-terminal α helix and
the three exposed loop segments β1 to β2, β3 to β4 and
β5 to β6, as well as the C terminus. After superposition of
the mainchain atoms (Figure 7a), we calculated the small-
est possible ellipsoid containing all Cα positions of the
same residues observed in the eight monomers with the
program GEM [51], and displayed the ellipsoids in program
O [47] (Figure 7b). In all but one of the loops as well as in
the N-terminal α helix, no concerted displacement is
observed. In loop β5 to β6, however, the observed atomic
positions of the eight monomers represent different snap-
shots of a concerted loop movement, yielding displace-
ments as large as 4.7 Å at the tip (His86). The loop itself
retains its conformation (Figures 7b,c), whereas residues
next to the loop serve as hinges, in good agreement with
the angular order parameter plot.
TGF-β1 is the only member of the cystine knot superfam-
ily whose structure has been determined in solution using
NMR techniques [32]. As the structures of the TGF-β1
and VEGF monomers are very similar, it is possible to
compare the conformational variability of TGF-β1 in solu-
tion with the ensemble of eight structures observed in the
crystal of VEGF. Both structures are of good quality, as
judged by a high number of restraints and high resolution,
respectively. In the TGF-β1 dimer, the rms difference of
the backbone relative to the mean is 0.71 Å when some
loops are excluded; this high deviation is attributed to a
hinge movement at the center of its four-stranded β sheet
[32]. Based on a simulation of a distance restraint refine-
ment using the coordinates from the crystal structure of
TGF-β2 as a starting model, the authors conclude that this
large hinge movement is due to the absence of long range
restraints and therefore an artifact of the refinement. The
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Figure 7
Superposition of the eight independent copies
of the VEGF monomer. (a) Cα representation of
the eight copies of VEGF after superposition on
the secondary structure elements. (b) Stereo
representation of the geometrically averaged
structure (red lines). At each Cα position the
smallest ellipsoid (blue) which fits all Cα atoms
of the eight monomers is displayed (calculated
with the program GEM [51]). (c) Stereo
drawing of the concerted loop motion observed
for loop β5 to β6 as illustrated by the colinear
elongation of the ellipsoids for residues 84–87.
The averaged structure is shown in red together
with two border structures in black.
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recent crystal structure of GDNF [36], however, shows pre-
cisely such hinge variation between the two dimers in the
asymmetric unit, thus, hinge movement may be a contribut-
ing factor to the high rms deviations observed in TGF-β1.
Such hinge motion is not observed for VEGF or PDGF,
probably due to the difference in dimerization mode.
Considering the monomer only, superimposing the first
17 structures of TGF-β1 (Brookhaven Protein Data Bank
entry code 1kla; monomer A) based on the N, Cα, C and
O atoms in the β strands and helix α2 gives an rms differ-
ence from the mean coordinates of 0.32 ± 0.09 Å, which is
comparable to the difference calculated for our eight VEGF
monomers. Through the use of 15N relaxation experi-
ments the authors identify only a single segment in the
finger region of TGF-β1 that shows significant local flexi-
bility on a picosecond time scale in solution. This segment
is equivalent to the tip of loop β5 to β6 in VEGF and is
limited to about eight residues. Interestingly, these are
the very residues to which we attribute a concerted loop
movement based on our analysis of the independent
monomers in our crystals (Figure 7c). Overall, the compar-
ison of these two cystine knot proteins yields a surpris-
ingly good correlation in the conformational flexibility of
the molecules in the crystal versus solution.
Receptor binding
VEGF binds to two different receptors: the KDR/Flk-1
receptor and the Flt-1 receptor. The extracellular portion
of both receptors consists of seven IgG-like domains, and
the receptors share 44% homology [2]. Charge reversal and
alanine scanning mutagenesis have allowed identification
of the receptor-binding epitope of VEGF for KDR/Flk-1
[22,25]. Five residues were found to contribute most of
the binding energy. These five residues (Phe17, Ile46,
Glu64, Gln79 and Ile83) are clustered into two different
patches, each of which extends across the VEGF dimer
interface (Figure 8). All five residues are located on one
face of the VEGF dimer, which we refer to as the recep-
tor-binding face. This face consists of the short three-
stranded β sheet (strands β2, β5 and β6) and loop β1 to β2
of one monomer together with the N-terminal α helix and
loop β3 to β4 of the second monomer. In PDGF, the
residues that have thus far been implicated in receptor
binding all map on the equivalent face [30,52,53].
The VEGF homologs PLGF, VEGF-B and VEGF-C,
differ in their ability to bind to different receptors. PLGF
only binds to Flt-1 and not to KDR [21]. Sequence align-
ments show that of the five most important KDR-binding
determinants of VEGF, four are totally conserved between
VEGF and PLGF, while the fifth residue is changed from
isoleucine to methionine (Figure 9). Ile46 is one of three
residues that contribute most to the KDR-binding energy
[25], and this single difference is likely to significantly
affect the affinity for KDR. However, other residues close-
by and displayed on the same binding face are also likely
to contribute to the changes in specificity. Non-conserva-
tive differences in these residues are Met18→Gln, Gln22→
Gly, Lys48→Ser, Asn62→Gly, Gly65→Asn, Pro85→Ser,
His86→Gly and Gln89→Pro. Of particular interest are the
differences in residues 85, 86 and 89 in the loop connect-
ing β5 to β6: these changes, involving two prolines and a
glycine, are likely to affect the observed movement of the
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Figure 8
Stereo representation of the receptor-binding
face of VEGF. The receptor-binding face is
built from strands β2, β5 and β6 from the first
monomer (blue) and helix α1 from the second
monomer (red) as well as adjacent loops. This
view of the molecule is generated from Figure 1
by an approximately 90° rotation around a
horizontal axis in the plane of the paper. The
most important binding determinants for the
KDR receptor, as identified by mutagenesis
[25], form two hot spots: Phe17′ and Gln79;
and Ile46, Glu64′ and Ile83 (shown in yellow).
We propose that residues accessible on the
same face (shown in gray) are responsible for
receptor-binding specificity among VEGF and
its homologs. For example, a limited number
of residues (namely Asp63′, Glu64′ and
Glu67′) have been identified to participate in
binding of VEGF to its Flt-1 receptor [22].
Glu67′ is part of the loop containing Asp63′
and Glu64′, and all three residues are
exposed on the receptor-binding face. (The
figure was drawn with the programs
MOLSCRIPT [65] and RASTER3D [66].)
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loop. We speculate that the expected change in loop flexi-
bility might be an important contribution to receptor
specificity. Other changes of interest are Asn62→Gly and
Gly65→Asn, because they are located near Glu64, a criti-
cal binding determinant of VEGF for KDR. As Glu64 is
also important for binding to Flt-1, it is unlikely that the
differences at positions 62 and 65 result in gross local con-
formational changes, therefore, these residues might be
involved in direct receptor contacts.
Although VEGF-C stimulates the autophosphorylation
of the KDR receptor [17], unlike VEGF it is not possi-
ble to coprecipitate VEGF-C with a KDR–IgG fusion
protein,  suggesting that the interaction of VEGF-C and
KDR is weak [18]. Of the five residues important for
binding of VEGF to KDR, only Glu64 and Ile83 are
present in VEGF-C (Figure 9). The differences in the
remaining four residues may suffice to explain the weak-
ened binding between VEGF-C and KDR, and it would
be interesting to test the importance of these four residues
using mutagenesis.
VEGF binding to the Flt-1 receptor appears to be mostly
mediated through loop β3 to β4 [22]. Of all single alanine
substitutions tried, only those at Asp63 and Glu64, which
are both located in this loop, were found to significantly
reduce affinity in a direct binding assay, without, however,
accounting for the entire binding energy [22]. These
residues are conserved in VEGF and PLGF, while in
VEGF-C, which does not bind to Flt-1, Asp63 is changed to
serine (Figure 9). This suggests that position 63 is impor-
tant for specificity.
Sequence alignments show that the Flt-1 receptor is
expected to be structurally similar to the KDR/Flk-1
receptor [2]. We believe, therefore, that VEGF binds in a
similar manner to both receptors. This is analogous to the
binding of human growth hormone to both the growth
hormone receptor and the prolactin receptor, for which
extensive mutagenesis and structural data are available
[54–56]. The crystal structures of these complexes reveal
that although significant differences are found in detail,
the overall arrangement of receptor and hormone is surpris-
ingly similar, and in both complexes the same set of
residues is buried at the interface. Even so, the relative
importance of the individual contact residues is different
for binding to the growth hormone or the prolactin recep-
tor. Therefore, receptor specificity can be achieved by
residues different from those contributing most to the
binding energy, thus decoupling binding and specificity
determinants [56]. We believe similar mechanisms operate
for the receptor binding of VEGF, PLGF and VEGF-C,
and it will be interesting to gain structural insights into
how these homologous growth factors bind to their recep-
tors and how specificity is achieved in each case.
Biological implications
Vascular endothelial growth factor (VEGF) is a highly
specific mitogen promoting the formation of blood
vessels in embryogenesis and wound healing. It is also
involved in pathological angiogenesis such as tumor
growth, diabetic retinopathy, and rheumatoid arthritis.
These biological properties make VEGF an important
therapeutic target, and it has been shown that anti-
VEGF antibodies can inhibit tumor growth in vivo. At
the molecular level, VEGF activity is mediated by its
interaction with two distinct receptors, KDR and Flt-1.
A detailed structural and functional characterization of
the interactions between VEGF and its receptors is a
prerequisite for the design of small-molecule antagonists.
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Figure 9
Sequence alignment of VEGF, PLGF, VEGF-B,
VEGF-C, PDGF-A and PDGF-B. The
secondary structure assignment in VEGF is
shown by arrows. Black boxes identify the
binding determinants of VEGF for the KDR
receptor [25]. Gray boxes identify residues
accessible on the same receptor-binding face
as the KDR-binding determinants in VEGF.
Mutations in these residues might be
responsible for differences in affinity and
selectivity within the VEGF group. Because of
the structural similarity between VEGF and
PDGF, and supported by the mutagenesis data
published so far, the same positions might be
responsible for receptor recognition by PDGF
[30,52,53]. (The sequences of PLGF, VEGF-B,
VEGF-C, PDGF-A and PDGF-B were obtained
from the Swissprot databank with accession
numbers P49763, P49765, P49769, P04085
and P01127, respectively.)
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The crystal structure of the receptor-binding domain of
VEGF shows that it is a member of the cystine knot
growth factor superfamily. A comprehensive mutagene-
sis analysis has revealed that the residues important for
KDR binding map in two patches on the same face of
the molecule, spanning across the dimer interface. The
main structural feature of this receptor-binding face is a
short three-stranded, antiparallel β sheet in one subunit,
which packs against the N-terminal α helix from the
other subunit. This interaction accounts for 65% of the
total surface buried within the dimer, and may be impor-
tant for the stability of the receptor-binding face.
Analysis of the conformational variability of VEGF
shows that the loop connecting strand β5 to β6 under-
goes a concerted movement. This loop is important for
binding to both KDR and Flt-1, therefore, the flexibility
of the loop might be functionally important in accessing
different conformations required for binding to these dis-
tinct receptors. Although the role of the VEGF homologs,
placenta growth factor (PLGF), VEGF-B and VEGF-
C, in the regulation of angiogenesis is still poorly under-
stood, multiple sequence alignment helps to explain at an
atomic level the differences in specificity of the VEGF
homologs towards KDR and Flt-1.
Compared to other cystine knot growth factors, VEGF
shows greatest structural similarity to platelet-derived
growth factor (PDGF). Three major differences are
observed between VEGF and PDGF, all in regions
important for receptor binding. A comparison of VEGF
with the structure of transforming growth factor (TGF)-β
reveals greater similarity than previously expected,
because a loop region that was missing in PDGF has a
conformation very similar to the analogous segment in
TGF-β; the similarity extends to the region identified 
as the receptor-binding face in VEGF. This structural
conservation suggests functional conservation, consis-
tent with limited mutagenesis data implicating this same
region of the monomers in PDGF and TGF-β for recep-
tor binding.
Materials and methods
Crystallization and data collection
A construct consisting of residues 8–109 of human VEGF was
expressed, refolded and purified as described [26]. Triclinic crystals
(P1, a = 45.5 Å, b = 68.5 Å, c = 85.8 Å, α = 105.4°, β = 93.71°,
γ = 101.49°) were grown from large sitting drops obtained by mixing
40 µl of protein solution (15 mg/ml protein in 20 mM Tris-HCl, pH 7.5,
0.4 M sodium chloride) with 40 µl of reservoir solution (14% PEG
3350, 10% isopropanol, 0.2 M ammonium acetate pH 5.6), and equili-
brating against 30 ml of reservoir solution. Crystals grew to a typical
size of 600 × 80 × 80 µm within four weeks. The crystals could be
flash-frozen directly from the drops, after increasing the isopropanol
content of the reservoir to 20% and equilibrating against the altered
reservoir for one week. (At the end of this period the crystals started to
disintegrate and monoclinic crystals appeared spontaneously. Similar
monoclinic crystals directly grown from high isopropanol conditions
were previously used to determine the structure of VEGF by multiple
isomorphous replacement methods (MIR) [25]).
A complete data set to 1.9 Å was collected from a single flash-frozen
crystal on beamline F1 (λ = 0.909 Å) at the Cornell High Energy Syn-
chrotron Source equipped with the Princeton CCD-detector. Two sets
of exposures, 184 images of 1° oscillation at a detector–crystal dis-
tance of 80 mm and 91 images of 2° oscillation at a distance of
120 mm, were processed independently with program DENZO, after
which the two data sets were scaled together with program
SCALEPACK [57]. A total of 180,803 observations was reduced to
72,050 unique reflections, with an overall Rmerge of 4.4% (12.7%
between 2.0 and 1.9 Å resolution). The resulting data set was 94%
complete in the resolution range between 20 and 1.90 Å (81% in the
shell between 2.0 and 1.9 Å resolution).
Molecular replacement
The structure was solved by MR using the 2.5 Å structure of VEGF pre-
viously solved by MIR techniques in space group P21 as a search
model [25], using a dimer with all atomic temperature factors set to
20 Å2. The rotation function was calculated with the program XPLOR
[58], using all reflections between 10 and 4 Å resolution and an inte-
gration sphere from 5 to 20 Å. After Patterson correlation refinement
[59] of the first 200 solutions, during which the two monomers within
the dimer were allowed independent adjustments, a set of eight solu-
tions with correlation coefficients between 0.15 to 0.10 stood out
clearly above the noise at 0.06. The eight rotation solutions repre-
sented the four VEGF dimers in the asymmetric unit, corresponding in
a Matthews parameter [60] of 2.7 Å3/Da.
The translation search was calculated with the program AMORE [61]
using reflections between 20 and 4.0 Å resolution. The first dimer was
arbitrarily positioned at the origin and an unambiguous solution was
found for the second dimer, with an R value of 55.9% and a correlation
of 15.6% (next position: R value = 57.6% and correlation coeffi-
cient = 10.8%). The subsequent translation search for the third and
fourth dimers increased the correlation to 24.4% and 33.1%, while
decreasing the R factor to 53% and 49.6%, respectively. Identical trans-
lation solutions were obtained when the order in which the rotated
dimers were translated into the unit cell was permutated. Inspection of
the model with the program O [47] revealed a convincing packing
scheme and the absence of any stereochemical clashes. In addition, con-
sistent with the correct space group assignment, each monomer has a
unique crystallographic packing environment.
Refinement
Before refinement, 10% of all measured reflections were set apart for
subsequent monitoring of the free R value [62]; these reflections were
selected in 20 thin resolution shells to remove possible bias resulting
from noncrystallographic symmetry. Rigid-body refinement of the MR
model to 3 Å resolution resulted in an R value of 41.6% (free R value
44.1%). The model was subsequently refined by alternating a total of 24
rounds of conventional refinement using program XPLOR [58] with visual
inspection and model building using the program O [47], while gradually
increasing the resolution to 1.93 Å. After several rounds of refinement the
native data set was corrected for observed anisotropy, the biggest differ-
ence of 14 Å2 being observed between the a* and c* axes.
Initially, water positions were derived from peaks greater than 4σ in a
Sigmaa-weighted [41] difference map; later 3.5σ peaks in a regular
Fo–Fc density map were considered. After each refinement round, water
molecules were removed if their temperature factors exceeded 80 Å2 or
displayed less than 1σ density in the resulting 2Fo–Fc density map.
At this stage of the refinement the crystallographic R value had dropped
to 20.9% for all reflections between 8 and 1.93 Å resolution, but the free
R value was still as high as 31.1% and could not be further decreased
through model rebuilding or incorporation of water molecules. To investi-
gate possible overfitting of the data, two series of omit maps [63] were
calculated: VEGF dimers were removed one by one, together with all
solvent molecules, and the remaining model subjected to simulated
annealing at 1000 K with the program XPLOR [58]; secondly, single
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monomers were deleted one by one and the remaining structure refined
against all data between 16 and 1.93 Å resolution using maximum likeli-
hood refinement with the program REFMAC [64]. Inspection of the
Sigmaa-weighted omit maps confirmed the correct placement of the
VEGF molecules and allowed only for minor adjustments at the very ter-
minal residues in the individual chains. After rebuilding, several rounds of
refinement with REFMAC using a bulk-solvent correction and all data
between 16 and 1.93 Å resolution resulted in a significant decrease from
3.9 to 2.0 Å2 in the rms deviation of the temperature factors of bonded
mainchain atoms. Prior to the last refinement round an explicit bulk-
solvent mask was calculated with XPLOR [58] and introduced into
REFMAC [64] using partial structure factors. Noncrystallographic sym-
metry restraints were gradually loosened throughout the refinement and
removed completely near the end, resulting in a drop in both the free R
value and the crystallographic R value of 0.9%. Refinement was halted
after the R value dropped to 20.9% (free R value = 27.2%) and no inter-
pretable difference density remained in the final (Fo–Fc) exp(iαc) electron-
density map.
Accession numbers
The coordinates have been deposited in the Brookhaven Protein Data
Bank for release on July 30, 1998; the accession code is 2VPF.
Acknowledgements
We thank Wayne Fairbrother for numerous scientific discussions, for doing
ensemble rms difference and order parameter calculations, and for critical
reading of the manuscript. We also thank the staff at CHESS for help with
beamline F1, and Trissa Elkins, Charles Eigenbrot, and Mike Randal for help
with data collection.
References
1. Folkman, J. (1995). Angiogenesis in cancer, vascular, rheumatoid and
other disease. Nat. Med. 1, 27–31.
2. Ferrara, N. (1995). The role of vascular endothelial growth factor in
pathological angiogenesis. Breast Cancer Res. Treat. 36, 127–137.
3. Dvorak, H.F., Brown, L.F., Detmar, M. & Dvorak, A.M. (1995). Vascular
permeability factor/vascular endothelial growth factor, microvascular
hyper-permeability and angiogenesis. Am. J. Pathol. 146, 1029–1039.
4. Neufeld, G., Tessler, S., Gitay-Goren, H., Cohen, T. & Levi, B.Z.
(1994). Vascular endothelial growth factor and its receptors. Prog.
Growth Factor Res. 5, 89–97.
5. Carmeliet, P., et al., & Andras, N. (1996). Abnormal blood vessel
development and lethality in embryos lacking a single VEGF allele.
Nature 380, 435–439.
6. Ferrara, N., et al., & Moore, M.W. (1996). Heterozygous embryonic
lethality induced by targeted inactivation of the VEGF gene. Nature
380, 439–442.
7. Kim, J.K., et al., & Ferrara, N. (1993). Inhibition of vascular endothelial
growth factor-induced angiogenesis suppresses tumour growth in
vivo. Nature 362, 841–844.
8. Aiello, L.P., et al., & King, G. (1994). Vascular endothelial growth in
occular fluid of patients with diabetic retinopathy and other retinal
disorders. N. Engl. J. Med. 331, 1480–1487.
9. Adamis, A.P., et al., & Yeo, K.-T. (1994). Increased vascular
endothelial growth factor in the vitreous of eyes with proliferative
diabetic retinopathy. Am. J. Ophthalmol. 118, 445–450.
10. Houck, K.A., Ferrara, N., Winer, J., Cachianes, G., Li, B. & Leung, D.W.
(1991). The vascular endothelial growth factor family: identification of
a fourth molecular species and characterization of alternative splicing
of RNA. Mol. Endocrinol. 5, 1806–1814.
11. Tischler, E., et al., & Abraham, J.A. (1991). The human gene for
vascular endothelial growth factor. Multiple protein forms are encoded
through alternative splicing of RNA. J. Biol. Chem. 266,
11947–11954.
12. Keyt, B.A., et al., & Ferrara, N. (1996). The carboxyl-terminal domain of
vascular endothelial growth factor is critical for its mitogenic potency.
J. Biol. Chem. 271, 7788–7795.
13. Leung, D.W., Cachianes, G., Kuang, W.-J., Goeddel, D.V. & Ferrara, N.
(1989). Vascular endothelial growth factor is a secreted angiogenic
mitogen. Science 246, 1306–1309.
14. Keck, P.J., et al., & Connolly, D.T. (1989). Vascular permeability factor,
an endothelial cell mitogen related to PDGF. Science 246,
1309–1312.
15. Maglione, D., Guerriero, V., Viglietto, G., Delli-Bovi, P. & Persico, M.G.
(1991). Isolation of a human placenta cDNA coding for a protein
related to the vascular permeability factor. Proc. Natl. Acad. Sci. USA
88, 9267–9271.
16. Olofsson, B., et al., & Eriksson, U. (1996). Vascular endothelial growth
factor B, a novel growth factor for endothelial cells. Proc. Natl. Acad.
Sci. USA 93, 2576–2581.
17. Joukov, V., et al., & Alitalo, K. (1996). A novel vascular endothelial
growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR
(VEGFR-2) receptor kinases. EMBO J. 15, 290–298.
18. Lee, J., Gray, A., Yuan, J., Luoh, S.-M., Avraham, H. & Wood, W.I.
(1996). Vascular endothelial growth factor-related protein: a ligand
and specific activator of the tyrosine kinase receptor Flt-4. Proc. Natl.
Acad. Sci. USA 93, 1988–1992.
19. Jeltsch, M., et al., & Alitalo, K. (1997). Hyperplasia of lymphatic vessels
in VEGF-C transgenic mice. Science 276, 1423–1425.
20. De Vries, C., Escobedo, J.A., Ueno, H., Houck, K., Ferrara, N. &
Williams, L.T. (1992). The fms-like tyrosine kinase, a receptor for
vascular endothelial growth factor. Science 255, 989–991.
21. Park, J.E., Keller, G.A. & Ferrara, N. (1993). The vascular endothelial
growth factor (VEGF) isoforms: differential deposition into the
subepithelial extracellular matrix and bioactivity of extracellular matrix-
bound VEGF. Mol. Biol. Cell. 4, 1317–1326.
22. Keyt, B.A., et al., & Ferrara, N. (1996). Identification of vascular
endothelial growth factor determinants for binding KDR and FLT-1
receptors. J. Biol. Chem. 271, 5638–5646.
23. Park, J.E., Chen, H., Winer, J., Houck, K. & Ferrara, N. (1994).
Placenta growth factor. Potentiation of vascular endothelial growth
factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1
but not to Flk-1/KDR. J. Biol. Chem. 269, 25646–25654.
24. Mustonen, T. & Alitalo, K. (1995). Endothelial receptor tyrosine
kinases involved in angiogenesis. J. Cell. Biol. 129, 895–898.
25. Muller, Y.A., Li, B., Christinger, H.W., Wells, J.A., Cunningham, B.C. &
De Vos, A.M. (1997). Vascular endothelial growth factor: crystal
structure and functional mapping of the kinase domain receptor
binding site. Proc. Natl. Acad. Sci. USA 94, 7192–7197.
26. Christinger, H.W., et al., & De Vos, A.M. (1996). Crystallization of the
receptor binding domain of vascular endothelial growth factor.
Proteins 26, 353–357.
27. Sun, P.D. & Davies, D.R. (1995). The cystine-knot growth-factor
superfamily. Annu. Rev. Biophys. Biomol. Struct. 24, 269–291.
28. McDonald, N.Q. & Hendrickson, W.A. (1993). A structural superfamily
of growth factors containing a cystine knot motif. Cell 73, 421–424.
29. Murray-Rust, J., et al., & Bradshaw, R.A. (1993). Topological
similarities in TGF-β2, PDGF-BB and NGF define a superfamily of
polypeptide growth factors. Structure 1, 153–159.
30. Oefner, C., D’Arcy, A., Winkler, F.K., Eggimann, B. & Hosang, M.
(1992). Crystal structure of human platelet-derived growth factor BB.
EMBO J. 11, 3921–3926.
31. Hinck, A.P., et al., & Torchia, D.A. (1996). Transforming growth factor
β1: three dimensional structure in solution and comparison with the X-
ray structure of transforming growth factor β2. Biochemistry 35,
8517–8534.
32. Daopin, S., Li, M. & Davies, D.R. (1993). Crystal structure of TGF-β2
refined at 1.8 Å resolution. Proteins 17, 176–192.
33. Schlunegger, M.P. & Grütter, M.G. (1993). Refined crystal structure of
human transforming growth factor-β2 at 1.95 Å resolution. J. Mol.
Biol. 231, 445–458.
34. Mittl, P.R.E., Priestle, J.P., Cox, D.A., McMaster, G., Cerletti, N. &
Grütter, M.G. (1996). The crystal structure of TGF-β3 and comparison
to TGF-β2: implications for receptor binding. Protein Sci. 5,
1261–1271.
35. Griffith, D.L., Keck, P.C., Sampath, T.K., Rueger, D.C. & Carlson, W.D.
(1996). Three-dimensional structure of recombinant human
osteogenic protein 1: structural paradigm for the transforming growth
factor β superfamily. Proc. Natl. Acad. Sci. USA 93, 878–883.
36. Eigenbrot, C. & Gerber, N. (1997). X-ray structure of glial cell-derived
neurotrophic factor at 1.9 Å resolution and implications for receptor
binding. Nat. Struct. Biol. 4, 435–438.
37. McDonald, N.Q., Lapatto, R., Murray-Rust, J., Gunning, J., Wlodawer, A.
& Blundell, T.L. (1991). New protein fold revealed by a 2.3 Å resolution
crystal structure of nerve growth factor. Nature 354, 411–414.
38. Holland, D.R., Cousens, L.S., Meng, W. & Matthews, B.W. (1994).
Nerve growth factor in different crystal forms displays structural
flexibility and reveals zinc binding sites. J. Mol. Biol. 239, 385–400.
39. Lapthorn, A.J., et al., & Isaacs, N.W. (1994). Crystal structure of
human chorionic gonadotropin. Nature 369, 455–461.
Research Article  Loop motion and receptor binding of VEGF Muller et al. 1337
40. Wu, H., Lustbader, J.W., Liu, Y., Canfield, R.E. & Hendrickson, W.A.
(1994). Structure of human chorionic gonadotropin at 2.6 Å resolution
from MAD analysis of the selenomethionyl protein. Structure 2,
545–558.
41. Read, R.J. (1986). Improved fourier coefficients for maps using partial
structures with errors. Acta Cryst. A 42, 140–149.
42. Laskowski, R.A., MacArthur, M.W., Moss, D.S. & Thornton, J.M.
(1993). Procheck: a program to check the stereochemical quality of
protein structures. J. Appl. Cryst. 26, 283–291.
43. Isaacs, N.W. (1995). Cystine knots. Curr. Opin. Struct. Biol. 5,
391–395.
44. Muller, Y.A., Schumacher, G., Rudolph, R. & Schulz, G.E. (1994). The
refined structures of a stabilized mutant and of wild-type pyruvate
oxidase from Lactobacillus plantarum. J. Mol. Biol. 237, 315–335.
45. Islam, S.A. & Weaver, D.L. (1990). Molecular interactions in protein
crystals: solvent accessible surface and stability. Proteins 8, 1–5.
46. Kossiakoff, A.A., Randal, M., Guenot, J. & Eigenbrot, C. (1992).
Variability of conformations at crystal contacts in BPTI represent true
low-energy structures: correspondence among lattice packing and
molecular dynamic structures. Proteins 14, 65–74.
47. Jones, T.A., Zou, J.-Y., Cowan, S.W. & Kjeldgaard, M. (1991). Improved
methods for building protein models in electron density maps and the
location of errors in these models. Acta Cryst. A 47, 110–119.
48. Qian, S.W., et al., & Roberts, A.B. (1996). Binding affinity of
transforming growth factor-beta for its type II receptor is determined
by the C-terminal region of the molecule. J. Biol. Chem. 271,
30656–30662.
49. Fairbrother, W.J., Champe, M.A., Christinger, H.W., Keyt, B.A. &
Starovasnik, M.A. (1997). 1H, 13C and 15N backbone assignment and
secondary structure of the receptor-binding domain of vascular
endothelial growth factor. Protein Sci. 6, in press.
50. Hyberts, S., Golberg, M.S., Havel, T.F. & Wagner, G. (1992). The
solution structure of eglin C based on measurements of many NOEs
and coupling constants and its comparison with X-ray structures.
Protein Sci. 1, 736–751.
51. Browner, M.F., Fauman, E.B. & Fletterick, R.J. (1992). Tracking
conformational states in allosteric transitions of phosphorylase.
Biochemistry 31, 11297–11304.
52. Engstrom, U., Engstrom, A., Ernlund, A., Westermark, B. & Heldin, C.-
H. (1992). Identification of a peptide antagonist for platelet-derived
growth factor. J. Biol. Chem. 267, 16581–16587.
53. LaRochelle, W.J., Pierce, J.H., May-Siroff, M., Giese, N. & Aaronson,
S.A. (1992). Five PDGF-B amino acid substitutions convert PDGF-A
to PDGF-B-like transforming molecule. J. Biol. Chem. 267,
17074–17077.
54. Cunningham, B.C. & Wells, J.A. (1991). Rational design of receptor-
specific variants of human growth hormone. Proc. Natl. Acad. Sci.
USA 88, 3407–3411.
55. De Vos, A.M., Ultsch, M. & Kossiakoff, A.A. (1992). Human growth
hormone and extracellular domain of its receptor: structure of the
complex. Science 225, 306–312.
56. Somers, W., Ultsch, M., De Vos, A.M. & Kossiakoff, A.A. (1994). The
X-ray structure of a growth hormone–prolactin receptor complex.
Nature 372, 478–481.
57. Otwinowski, Z. (1993). Oscillation data reduction program. In
Proceedings of the CCP4 Study Weekend: Data Collection and
Processing. (Sawyer, L., Isaacs, N. & Bailey, S., eds). pp. 56–62,
SERC Daresbury Laboratory, UK.
58. Brünger, A.T., Kuriyan, J. & Karplus, M. (1987). Crystallographic R
factor refinement by molecular dynamics. Science 235, 458–460.
59. Brünger, A.T. (1990). Extension of molecular replacement: a new
search strategy based on Patterson correlation refinement. Acta Cryst.
A 46, 46–57.
60. Matthews, B.W. (1968). Solvent content of protein crystals. J. Mol.
Biol. 33, 491–497.
61. CCP4. (1994). The CCP4 suite: programs for protein crystallography.
Acta Cryst. D 50, 760–763.
62. Brünger, A.T. (1992). The free R value: a novel statistical quantity for
assessing the accuracy of crystal structures. Nature 355, 472–475.
63. Bhat, T.N. & Cohen, G.H. (1984). OMITMAP: an electron density map
suitable for the examination of errors in a macromolecular model. J.
Appl. Cryst. 17, 244–248.
64. Murshudov, G.N., Vagin, A.A. & Dodson, E.J. (1997). Refinement of
macromolecular structures by the maximum-likelihood method. Acta
Cryst. D 53, 240–255.
65. Kraulis, P.J. (1991). MOLSCRIPT: a program to produce both detailed
and schematic plots of protein structures. J. Appl. Cryst. 24, 946–950.
66. Merrit, E.A. & Murphy, M.E.P. (1994). Raster3D version 2.0, a program
for photorealistic molecular graphics. Acta Cryst. D 50, 869–873.
67. Keck, R.G., Berleau, L., Harris, R. & Keyt, B.A. (1997). Disulfide
structure of the heparin binding domain in vascular endothelial growth
factor: characterization of posttranslational modifications in VEGF.
Arch. Biochem. Biophys. 344, 103–113.
1338 Structure 1997, Vol 5 No 10
